- Findings from Analysis Evaluating Test In Newly Diagnosed, Clinically High-Risk Disease to be Highlighted in ASTRO Press Program - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 14, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced that new data further validating the clinical utility of the
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 13, 2021-- Veracyte, Inc ., (Nasdaq: VCYT) announced today the publication of new data demonstrating that the company’s Decipher Bladder genomic classifier accurately identifies bladder tumors that are most likely to respond to chemotherapy prior
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 12, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Tuesday, November 9 . Company management will host a conference call and webcast to
Findings to be shared in oral presentation at CHEST Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating that the Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic
Company begins making novel, noninvasive test available to limited number of clinical sites to support more timely, accurate lung nodule diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that new expanded clinical validation data
- Expanded clinical validation data demonstrate Percepta Nasal Swab test performance across nodule sizes and cancer stages in early lung cancer assessment - - Findings reinforce value of Percepta GSC and Envisia GC in clinical decision-making and patient care - SOUTH SAN FRANCISCO, Calif.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that its Decipher ® Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines for Oncology to guide
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 1, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced that it has appointed Joshua Klopper , M.D., as medical director of Endocrinology. Dr. Klopper is a nationally recognized endocrinologist who
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 31, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global diagnostics company, today announced that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a fireside chat at the Morgan Stanley Virtual
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 23, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global diagnostics company, announced today that it has been awarded a Top Workplaces honor by the Bay Area News Group for the eighth consecutive year. The annual award is based solely on employee
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
